Literature DB >> 1851325

[Acute myocardial infarct following chemotherapy for testicular carcinoma: on the coronary toxicity of cytostatic agents].

G Borek1, F Gebel, H R Jenzer.   

Abstract

Two young patients who had been treated with cisplatin and bleomycin for testicular cancer developed acute myocardial infarction. 8 additional cases of premature myocardial infarction following chemotherapy for testicular cancer have been reported in the literature. The infarctions occurred several months or years after chemotherapy while most patients were in complete remission and had no significant risk factors for coronary artery disease. However, the pathogenesis of the assumed coronary toxicity associated with antineoplastic agents, usually with cisplatin and bleomycin, is not well understood; lesions of the endothelium with obstructive coronary fibrosis as well as disorders of the clotting system and coronary vasospasm have been considered as possibilities. We conclude that in patients treated for testicular cancer, special attention should be paid to symptoms suggestive of coronary artery disease.

Entities:  

Mesh:

Year:  1991        PMID: 1851325

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  3 in total

1.  Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea.

Authors:  H Kälsch; H Wieneke; R Erbel
Journal:  Herz       Date:  2010-09       Impact factor: 1.443

Review 2.  Myocardial infarction in young patients with Hodgkin's disease--potential pathogenic role of radiotherapy, chemotherapy, and splenectomy.

Authors:  K H Scholz; C Herrmann; U Tebbe; J M Chemnitius; U Helmchen; H Kreuzer
Journal:  Clin Investig       Date:  1993-01

3.  Aspartate 338 contributes to the cationic specificity and to driver-amino acid coupling in the insect cotransporter KAAT1.

Authors:  S A Mari; A Soragna; M Castagna; E Bossi; A Peres; V F Sacchi
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.